<p>Astrazeneca: Baxdrostat achieved the primary endpoint and all secondary endpoints in the BaxHTN Phase III trial. The 2 mg dose of Baxdrostat reduced systolic blood pressure by 15.7 mmHg from baseline levels. Baxdrostat was generally well tolerated, with no unexpected safety issues identified</p>

<p>Astrazeneca: Baxdrostat achieved the primary endpoint and all secondary endpoints in the BaxHTN III trial. The 2 mg dose of Baxdrostat reduced systolic blood pressure by 15.7 mmHg from baseline. Baxdrostat was generally well tolerated, with no unexpected safety issues identified</p>

News